Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

NCT00267683 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped This trial was terminated due to low recruitment

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin aspart
DRUG: glibenclamide

Sponsor

Novo Nordisk A/S